NASDAQ:EKSOEkso Bionics Stock Price, Forecast & News

$5.18

+0.23 (+4.65 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$4.78

Now: $5.18▼

$5.30

50-Day Range

$2.91

MA: $3.58▼

$4.95

52-Week Range

$2.25

Now: $5.18▼

$20.85

Volume148,428 shs

Average Volume148,351 shs

Market Capitalization$30.25 million

P/E RatioN/A

Dividend YieldN/A

Beta2.02

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke. The company's Ekso device is primarily used in a hospital and rehabilitation setting. The company has a license agreement with Lockheed Martin Corporation, Regents of the University of California, and Garrett Brown, as well as with OttoBock Healthcare Products Gmbh. The company was founded in 2005 and is headquartered in Richmond, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Ekso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.40, Ekso Bionics has a potential upside of 42.9% from its current price of $5.18.
Amount of Analyst Coverage
Ekso Bionics has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Ekso Bionics has received 294 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ekso Bionics has received 248 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ekso Bionics has received 54.24% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ekso Bionics and other stocks. Vote “Outperform” if you believe EKSO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe EKSO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ekso Bionics does not currently pay a dividend.
Dividend Growth
Ekso Bionics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ekso Bionics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 24.30% of the stock of Ekso Bionics is held by insiders.
Percentage Held by Institutions
Only 23.46% of the stock of Ekso Bionics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Ekso Bionics are expected to grow in the coming year, from ($1.94) to ($1.04) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ekso Bionics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ekso Bionics is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ekso Bionics has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.37 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry General industrial machinery,

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:EKSO

Previous SymbolOTCMKTS:EKSOD

CUSIPN/A

CIK1549084

Webwww.eksobionics.com

Phone510-984-1761

Debt

Debt-to-Equity Ratio0.11

Current Ratio1.86

Quick Ratio1.53

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$13.92 million

Price / Sales2.17

Cash FlowN/A

Price / Cash FlowN/A

Book Value$1.17 per share

Price / Book4.43

Profitability

EPS (Most Recent Fiscal Year)($3.45)

Net Income$-12,130,000.00

Net Margins-68.97%

Return on Equity-210.43%

Return on Assets-59.23%

Miscellaneous

Employees77

Outstanding Shares5,840,000

Market Cap$30.25 million

Next Earnings Date8/6/2020 (Estimated)

OptionableNot Optionable

Receive EKSO News and Ratings via Email

Sign-up to receive the latest news and ratings for EKSO and its competitors with MarketBeat's FREE daily newsletter.

Ekso Bionics (NASDAQ:EKSO) Frequently Asked Questions

How has Ekso Bionics' stock been impacted by COVID-19 (Coronavirus)?

Ekso Bionics' stock was trading at $0.2616 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EKSO stock has increased by 1,880.1% and is now trading at $5.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ekso Bionics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ekso Bionics.

When is Ekso Bionics' next earnings date?

Ekso Bionics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Ekso Bionics.

How were Ekso Bionics' earnings last quarter?

Ekso Bionics Holdings Inc (NASDAQ:EKSO) announced its quarterly earnings results on Thursday, April, 30th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.17. The company had revenue of $1.47 million for the quarter. Ekso Bionics had a negative return on equity of 210.43% and a negative net margin of 68.97%. View Ekso Bionics' earnings history.

When did Ekso Bionics' stock split? How did Ekso Bionics' stock split work?

Ekso Bionics shares reverse split before market open on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 4th 2016. An investor that had 100 shares of Ekso Bionics stock prior to the reverse split would have 14 shares after the split.

What guidance has Ekso Bionics issued on next quarter's earnings?

Ekso Bionics updated its first quarter 2020 After-Hours earnings guidance on Thursday, April, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.4-1.5 million, compared to the consensus revenue estimate of $3.63 million.

What price target have analysts set for EKSO?

3 brokerages have issued twelve-month target prices for Ekso Bionics' shares. Their forecasts range from $1.20 to $13.00. On average, they expect Ekso Bionics' stock price to reach $7.40 in the next twelve months. This suggests a possible upside of 42.9% from the stock's current price. View analysts' price targets for Ekso Bionics.

What are Wall Street analysts saying about Ekso Bionics stock?

Here are some recent quotes from research analysts about Ekso Bionics stock:

1. According to Zacks Investment Research, "Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company's operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. " (4/1/2020)
2. Aegis analysts commented, "We think conversion rate is an interesting metric to follow as it is representative of accounts which trialed the Ekso GT via the rental program, and then decided to make the capital commitment, which is significant, at around $130K per Ekso GT." (8/8/2019)

Has Ekso Bionics been receiving favorable news coverage?

News coverage about EKSO stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ekso Bionics earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutEkso Bionics.

Who are some of Ekso Bionics' key competitors?

Some companies that are related to Ekso Bionics include Supreme Cannabis (FIRE), CorMedix (CRMD), InflaRx (LUMO), 22nd Century Group (XXII), Oncolytics Biotech (ONC), BeyondAirInc . (XAIR), Shield Therapeutics (STX), Outlook Therapeutics (OTLK), Senseonics (SENS), Pure Bioscience (PURE), Georgia Healthcare Group (GHG), Recro Pharma (REPH), Checkpoint Therapeutics (CKPT), Venus Concept (VERO) and Ampliphi Biosciences (APHB). View all competitors.

What other stocks do shareholders of Ekso Bionics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include TransEnterix (TRXC), Amplify Energy (AMPY), Amplify Energy (AMPY), Chesapeake Energy (CHK), XOMA (XOMA), OrganiGram (OGI), Zosano Pharma (ZSAN), Infinity Augmented Reality (ALSO), KushCo (KSHB) and Miragen Therapeutics (MGEN).

Who are Ekso Bionics' key executives?

Ekso Bionics' management team includes the following people:

Mr. Steven A. Sherman, Exec. Chairman (Age 73)
Mr. Jack Peurach, Pres, CEO & Director (Age 53)
Mr. John F. Glenn, CFO & Sec. (Age 57)
Mr. William Shaw, Chief Commercial Officer (Age 45)
Ms. Foon Lim Chwee, Pres of APAC

What is Ekso Bionics' stock symbol?

Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO."

Who are Ekso Bionics' major shareholders?

Ekso Bionics' stock is owned by a number of institutional and retail investors. Top institutional investors include Intellectus Partners LLC (2.16%), BlackRock Inc. (1.03%) and WINTON GROUP Ltd (0.23%). View institutional ownership trends for Ekso Bionics.

Which major investors are selling Ekso Bionics stock?

EKSO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., WINTON GROUP Ltd, and Intellectus Partners LLC. View insider buying and selling activity for Ekso Bionics.

How do I buy shares of Ekso Bionics?

Shares of EKSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ekso Bionics' stock price today?

One share of EKSO stock can currently be purchased for approximately $5.18.

How big of a company is Ekso Bionics?

Ekso Bionics has a market capitalization of $30.25 million and generates $13.92 million in revenue each year. The company earns $-12,130,000.00 in net income (profit) each year or ($3.45) on an earnings per share basis. Ekso Bionics employs 77 workers across the globe.

What is Ekso Bionics' official website?

The official website for Ekso Bionics is www.eksobionics.com.

How can I contact Ekso Bionics?

Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The company can be reached via phone at 510-984-1761 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff